RxDoctor Payments Data

Omar Moore, MD

Clinical Neurophysiology · Jacksonville, FLNPI 1487072245

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $241 and has fallen 56.4% since, to $105 in 2025.

$687in general payments, 2019–2025

Across 31 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$111
  • Sanofi$106
  • SK Life Science, Inc.$58
  • Teva Pharmaceuticals USA, Inc.$52
  • Lundbeck LLC$49
  • UCB, Inc.$47
  • plus $266 from 13 others

What the payments were for

  • Food & beverage$687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$257,307
Medicare patients
1,032
Services billed
4,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam22$33,759
Lacosamide14$1,785
Gabapentin50$812
Levetiracetam36$566
Methocarbamol44$491
Lamotrigine46$485
Baclofen18$481
Zonisamide12$334
Pregabalin11$268
Phenobarbital19$258
Tizanidine Hcl27$246
Propranolol Hcl11$162
Duloxetine Hcl12$153
Topiramate24$111
Donepezil Hcl23$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$47$33,75922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →